PRQR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

ProQR Therapeutics BV

NASDAQ | PRQR

2.34

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$248.62M

Market Cap

-

P/E Ratio

-0.47

EPS

$3.92

52 Week High

$1.07

52 Week Low

HEALTHCARE

Sector

PRQR Chart

Recent Chart
Price Action

PRQR Technicals

Tags:

PRQR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $19M
Total Revenue $19M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$30M
Selling General And Administrative $14M
Research And Development $36M
Operating Expenses $49M
Investment Income Net -
Net Interest Income $2.2M
Interest Income $3.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$28M
Income Tax Expense -$197K
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$24M
Net Income -$28M

Revenue & Profitability

Earnings Performance

PRQR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $168M
Total Current Assets $154M
Cash And Cash Equivalents At Carrying Value $149M
Cash And Short Term Investments $149M
Inventory -
Current Net Receivables $2M
Total Non Current Assets $14M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments -
Other Current Assets $4.4M
Other Non Current Assets -
Total Liabilities $79M
Total Current Liabilities $39M
Current Accounts Payable $16K
Deferred Revenue -
Current Debt -
Short Term Debt $6.1M
Total Non Current Liabilities $40M
Capital Lease Obligations $13M
Long Term Debt -
Current Long Term Debt $4.6M
Long Term Debt Noncurrent -
Short Long Term Debt Total $17M
Other Current Liabilities $33M
Other Non Current Liabilities -
Total Shareholder Equity $89M
Treasury Stock -
Retained Earnings -$427M
Common Stock $4.3M
Common Stock Shares Outstanding $82M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow -$36M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.8M
Capital Expenditures $1.4M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$4.1M
Cashflow From Financing $70M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$28M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $19M
Total Revenue $19M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$30M
Selling General And Administrative $14M
Research And Development $36M
Operating Expenses $49M
Investment Income Net -
Net Interest Income $2.2M
Interest Income $3.3M
Interest Expense $1.1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.8M
Income Before Tax -$28M
Income Tax Expense -$197K
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$27M
Ebitda -$24M
Net Income -$28M

PRQR News

PRQR Profile

ProQR Therapeutics BV Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ProQR Therapeutics BV, based in Leiden, the Netherlands, is a forward-looking biopharmaceutical company focused on developing RNA-based therapies for severe genetic disorders. With a promising pipeline that encompasses both rare and more common diseases, the company leverages its proprietary technology platform to create innovative treatments aimed at addressing the underlying causes of these conditions. Committed to advancing the field of genetic medicine, ProQR is positioned to make a meaningful impact on patient outcomes through its pioneering research and development efforts in therapeutics.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.